Should I Buy NSPR? NSPR 2026 Analysis

Should You Buy InspireMD Inc (NSPR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.650

1 Day change

52 Week Range

3.800

Analysis Updated At

2026/01/26

InspireMD Inc (NSPR) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits bearish technical indicators, lacks positive trading sentiment, and has no significant news or catalysts to drive near-term growth. While the financial performance shows improvement in revenue and margins, the company remains unprofitable with a negative EPS. Given these factors, it is better to hold off on investing in this stock at the moment.

Technical Analysis

The technical indicators for NSPR are bearish. The MACD histogram is below 0 and negatively contracting, the RSI is neutral at 40.396, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 1.655, with key support at 1.533 and resistance at 1.778.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Revenue increased by 39.39% YoY in Q3 2025, and gross margin improved by 49.72% YoY, indicating operational improvements.

Neutral/Negative Catalysts

No recent news or significant trading trends from hedge funds, insiders, or Congress. The stock is projected to decline slightly in the next day, week, and month.

Financial Performance

In Q3 2025, InspireMD Inc reported a revenue increase of 39.39% YoY to $2,523,000. Net income improved by 61.06% YoY but remains negative at -$12,708,000. EPS improved by 6.25% YoY to -0.17, and gross margin increased by 49.72% to 34.24%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available for NSPR.

1 Analyst Rating

Wall Street analysts forecast NSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NSPR is 5 USD with a low forecast of 5 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.650

Low

Averages

High

Current: 1.650

Low

Averages

High

Piper Sandler

Overweight

downgrade

AI Analysis

2025-05-12

Reason

Piper Sandler

Price Target

AI Analysis

2025-05-12

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on InspireMD to $4 from $4.50 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results with sales above its expectations. The company pushed out expectations for FDA approval for its CGuard Prime stent to Q3 2025 from the first half of 2025 due to circumstances beyond the company's control. There was also a slight wiggle to expected U.S. launch timelines for the company's SwitchGuard TCAR system in development to late 2026, Piper adds.

NSPR Should I Buy

NSPR Should I Buy

Should You Buy InspireMD Inc (NSPR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch